R&D Pipeline

X4 Pharmaceuticals, focused on therapeutic opportunities targeting the CXCR4 receptor

14 May 2024
2 min read

X4 Pharmaceuticals is a biotech company specialized in the development of therapeutic drugs focusing on CXCR4 and immunological biology. The company maintains its professional strengths at the corporate headquarters in Boston, USA, and its center of excellence in Vienna, Austria, continuously driving forward its patient-centered mission. X4 is advancing treatment developments for patients with rare immunological diseases and groups with significant unmet medical needs by researching and promoting innovative therapies.

图形用户界面, 网站

描述已自动生成

On April 29th, X4 Pharmaceuticals announced that the U.S. FDA had approved XOLREMDI™ (Mavorixafor) capsules for the treatment of patients aged 12 and older with WHIM syndrome, to increase the number of mature neutrophils and lymphocytes in the circulation. WHIM syndrome is a rare, congenital immune deficiency disorder and chronic neutropenia characterized by warty lesions, hypogammaglobulinemia, susceptibility to infections, and bone marrow retention of neutrophils.

Currently, the company is working to expand the application of Mavorixafor to a broader patient population and is about to launch a pivotal global Phase III clinical trial targeting certain patients with chronic neutropenia.

图形用户界面

低可信度描述已自动生成

The following is the company presentation material updated in April 2024 by X4 Corporation:

X4 Corporation is a typical biotechnology company focused on the biology and clinical drug development targeting a single receptor, CXCR4.

图形用户界面, 应用程序

描述已自动生成

There has been no innovative drug development progress for chronic neutropenia over the past 30 years.

图形用户界面, 文本

描述已自动生成

文本

描述已自动生成

Mavorixafor: Verified to be effective in alleviating neutropenia and lymphocytopenia.

图形用户界面, 文本, 应用程序

描述已自动生成

For more information, please click the image below to access the Synapse database.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Grants Approval for WestGene's mRNA Cancer Treatment Vaccine
Latest Hotspot
3 min read
FDA Grants Approval for WestGene's mRNA Cancer Treatment Vaccine
14 May 2024
WestGene proudly declares a significant breakthrough as the FDA grants IND approval for its mRNA-based cancer vaccine, WGc-043.
Read →
PeptiDream, a company specializing in the research and development of peptide drugs
R&D Pipeline
4 min read
PeptiDream, a company specializing in the research and development of peptide drugs
14 May 2024
PeptiDream is a biotechnology company based in Japan, focused on the development of innovative macrocyclic peptide drugs.
Read →
Revance enters the American medical market by introducing DAXXIFY® to treat cervical dystonia
Latest Hotspot
3 min read
Revance enters the American medical market by introducing DAXXIFY® to treat cervical dystonia
14 May 2024
Revance Therapeutics, Inc. has initiated the market release of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, aimed at treating cervical dystonia.
Read →
Shionogi & Co. and Maze Therapeutics Announce Global Licensing Deal for Innovative Pompe Disease Therapy, MZE001
Latest Hotspot
3 min read
Shionogi & Co. and Maze Therapeutics Announce Global Licensing Deal for Innovative Pompe Disease Therapy, MZE001
14 May 2024
Shionogi & Co., Ltd. along with Maze Therapeutics, Inc. have declared a global exclusive licensing deal for MZE001, an innovative therapy aimed at addressing Pompe Disease.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.